A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Inclusion Criteria:

• Capable of giving signed informed consent as described in protocol, which includescompliance with the requirements and restrictions listed in the informed consentform (ICF), and in this protocol.

• Participant must be 18 to 55 years of age inclusive, at the time of signing theinformed consent.

• Participants who are overtly healthy as determined by the investigator or medicallyqualified designee based on medical evaluation including medical history, laboratorytests, physical, and cardiac examination.

• Participant is a nonsmoker who has not used tobacco- or nicotine- containingproducts (eg., nicotine patch) for at least 6 months before administration of thefirst study intervention.

• Body mass index (BMI) within the range 18.0 to 30 kg/m2 (inclusive) at screening,with bodyweight above/equal to 50 kg.

• Female, of non childbearing potential only. Females must not be pregnant orbreastfeeding, and must be documented as a woman of nonchildbearing potential. Anegative pregnancy test is required.

• Male study participants of reproductive potential must agree to use adequatecontraception when sexually active. From signing of the ICF until at least 3 monthsafter the last dose of study intervention, and refrain from sperm donation duringstudy intervention and for 6 months after the last dose of study intervention.

• Participant must be willing to comply with dietary and fluid requirements during thestudy period (including abstaining from alcohol use).

Exclusion Criteria:

• Existing relevant diseases of vital organs (e.g., liver diseases, heart diseases,gastrointestinal diseases, interstitial lung disease, renal diseases), centralnervous system (for example seizures) or other organs (e.g., diabetes mellitus).

• Incompletely cured pre-existing diseases for which it can be assumed that theabsorption, distribution, metabolism, elimination, and effects of the studyintervention will not be normal.

• Febrile illness within 4 weeks prior to admission to the clinic.

• Any relevant diseases within 4 weeks prior to the first study interventionadministration as judged by the investigator.

• A medical history of risk factors for Torsades de pointes (e.g., family history oflong QT syndrome) or other clinically significant arrhythmias as judged by theinvestigator.

• Known severe allergies, allergies requiring therapy with corticosteroids,significant non-allergic drug reactions, or (multiple) drug allergies (excludingseasonal allergies such as non-severe hay fever that are asymptomatic and untreatedduring the time of study conduct).

• Known history of hypersensitivity (or known allergic reaction) to BAY2927088 relatedcompounds, or any components of the formulation, itraconazole or carbamazepine (HLA-A 31:01 or HLA-B 15:02 allele for Arm 2 only)

• History of known or suspected malignant tumors.

• Participants with any type of ongoing psychiatric disorder, especially any mooddisorders including medical history with suicidal ideation and/or suicide attempts,which may disable the participant to consent.

• History of clinically relevant depression, or suicidal ideation or behavior.